RESUMEN
OBJECTIVE: Shenfu injection (SFI) is commonly used for cardiac dysfunction in China. Adenosine receptors have been reported to exert anti-fibrosis effects. The intent of this study was to evaluate that SFI attenuates cardiac fibrosis through activating of adenosine A2a receptor (A2aR) in rats with myocardial ischemia-reperfusion (MI/R). METHODS: Sprague Dawley male rats were randomly divided into five groups, nine rats in each group. Injections in all rat groups were carried out prior to reperfusion, and in the sham and MI/R groups, only vehicle was injected. Injections in the remaining group were as follows: 5 mL/kg in the SFI group; 15 mg/kg nicorandil in the A2R agonist group; and 5 mL/kg SFI plus 5 mg/kg MSX-3 in the SFI + A2aR antagonist group. Changes in cyclic adenosine monophosphate (cAMP) and the development of myocardial infarction and cardiac fibrosis were documented among the groups. Additionally, the levels of A2aR, collagen â , collagen â ¢, fibronectin, and matrix metalloproteinase-9 (MMP-9) were measured. RESULTS: Following injection with SFI or nicorandil, the cAMP concentration, infarct area, and cardiac fibrosis induced by MI/R injury were significantly decreased (p < 0.05). Additionally, the levels of collagen â , collagen â ¢, fibronectin, and MMP-9 were clearly suppressed by SFI or nicorandil when compared with the MI/R group (p<0.01). However, the protective effects of SFI were counteracted by MSX-3. A negative correlation between A2aR and collagen I and collagen III was found (p = 0.00). CONCLUSION: SFI activated the A2aR to reduce myocardial fibrosis caused by MI/R injury, which provided an underlying mechanism of action of SFI.
Asunto(s)
Antagonistas del Receptor de Adenosina A2/uso terapéutico , Antiarrítmicos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Fibrosis/tratamiento farmacológico , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Nicorandil/uso terapéutico , Receptor de Adenosina A2A/efectos de los fármacos , Animales , Antiarrítmicos/administración & dosificación , China , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Humanos , Masculino , Nicorandil/administración & dosificación , Ratas , Ratas Sprague-DawleyRESUMEN
6-Hydroxydopamine (6-OHDA) is the most used toxin in experimental Parkinson's disease (PD) models. 6-OHDA shows high affinity for the dopamine transporter and once inside the neuron, it accumulates and undergoes non-enzymatic auto-oxidation, promoting reactive oxygen species (ROS) formation and selective damage of catecholaminergic neurons. In this way, our group has established a 6-OHDA in vitro protocol with rat striatal slices as a rapid and effective model for screening of new drugs with protective effects against PD. We have shown that co-incubation with guanosine (GUO, 100 µM) prevented the 6-OHDA-induced damage in striatal slices. As the exact GUO mechanism of action remains unknown, the aim of this study was to investigate if adenosine A1 (A1R) and/or A2A receptors (A2AR) are involved on GUO protective effects on striatal slices. Pre-incubation with DPCPX, an A1R antagonist prevented guanosine effects on 6-OHDA-induced ROS formation and mitochondrial membrane potential depolarization, while CCPA, an A1R agonist, did not alter GUO effects. Regarding A2AR, the antagonist SCH58261 had similar protective effect as GUO in ROS formation and mitochondrial membrane potential. Additionally, SCH58261 did not affect GUO protective effects. The A2AR agonist CGS21680, although, completely blocked GUO effects. Finally, the A1R antagonist DPCPX, and the A2AR agonist CGS21680 also abolished the preventive guanosine effect on 6-OHDA-induced ATP levels decrease. These results reinforce previous evidence for a putative interaction of GUO with A1R-A2AR heteromer as its molecular target and clearly indicate a dependence on adenosine receptors modulation to GUO protective effect.
Asunto(s)
Guanosina/farmacología , Enfermedades Mitocondriales/prevención & control , Neostriado/metabolismo , Fármacos Neuroprotectores/farmacología , Oxidopamina/toxicidad , Receptor de Adenosina A1/efectos de los fármacos , Receptor de Adenosina A2A/efectos de los fármacos , Estallido Respiratorio/efectos de los fármacos , Antagonistas del Receptor de Adenosina A1/farmacología , Animales , Evaluación Preclínica de Medicamentos , Técnicas In Vitro , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Neostriado/efectos de los fármacos , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Xantinas/uso terapéuticoRESUMEN
The median preoptic nucleus (MnPN) and the ventrolateral preoptic area (VLPO) are two hypothalamic regions that have been implicated in sleep regulation, and both nuclei contain sleep-active GABAergic neurons. Adenosine is an endogenous sleep regulatory substance, which promotes sleep via A1 and A2A receptors (A2AR). Infusion of A2AR agonist into the lateral ventricle or into the subarachnoid space underlying the rostral basal forebrain (SS-rBF), has been previously shown to increase sleep. We examined the effects of an A2AR agonist, CGS-21680, administered into the lateral ventricle and the SS-rBF on sleep and c-Fos protein immunoreactivity (Fos-IR) in GABAergic neurons in the MnPN and VLPO. Intracerebroventricular administration of CGS-21680 during the second half of lights-on phase increased sleep and increased the number of MnPN and VLPO GABAergic neurons expressing Fos-IR. Similar effects were found with CGS-21680 microinjection into the SS-rBF. The induction of Fos-IR in preoptic GABAergic neurons was not secondary to drug-induced sleep, since CGS-21680 delivered to the SS-rBF significantly increased Fos-IR in MnPN and VLPO neurons in animals that were not permitted to sleep. Intracerebroventricular infusion of ZM-241385, an A2AR antagonist, during the last 2 h of a 3-h period of sleep deprivation caused suppression of subsequent recovery sleep and reduced Fos-IR in MnPN and VLPO GABAergic neurons. Our findings support a hypothesis that A2AR-mediated activation of MnPN and VLPO GABAergic neurons contributes to adenosinergic regulation of sleep.
Asunto(s)
Neuronas GABAérgicas/fisiología , Hipotálamo/fisiología , Área Preóptica/fisiología , Receptor de Adenosina A2A/fisiología , Sueño/fisiología , Adenosina/administración & dosificación , Adenosina/análogos & derivados , Adenosina/farmacología , Agonistas del Receptor de Adenosina A2/administración & dosificación , Agonistas del Receptor de Adenosina A2/farmacología , Antagonistas del Receptor de Adenosina A2/administración & dosificación , Antagonistas del Receptor de Adenosina A2/farmacología , Animales , Neuronas GABAérgicas/efectos de los fármacos , Infusiones Intraventriculares , Masculino , Microinyecciones , Modelos Animales , Fenetilaminas/administración & dosificación , Fenetilaminas/farmacología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Ratas , Ratas Sprague-Dawley , Receptor de Adenosina A2A/efectos de los fármacos , Sueño/efectos de los fármacos , Triazinas/administración & dosificación , Triazinas/farmacología , Triazoles/administración & dosificación , Triazoles/farmacologíaRESUMEN
Serum deprivation-induced neuronal-like PC12 cell apoptosis was used as an ischemic/hypoxic model to screen neuroprotective compounds from the rhizomes of Gastrodia elata, a traditional Chinese medicine. Two active compounds, bis(4-hydroxybenzyl)sulfide (1) and N6-(4-hydroxybenzyl)adenine riboside (2), together with 15 known compounds were obtained from the active fraction. Compound 2 was further elucidated by chemical synthesis. Compounds 1 and 2 potently prevented PC12 cell apoptosis in concentration-dependent manners with EC50 values of 7.20 microM and 3.7 x 10-8 M, respectively, and IC50 values of 42.90 microM (Ki 24.10 microM) and 4.660 microM (Ki 2.620 microM), respectively, in an adenosine A2A receptor binding assay.
Asunto(s)
Adenosina/análogos & derivados , Medicamentos Herbarios Chinos/farmacología , Gastrodia/química , Fármacos Neuroprotectores/farmacología , Plantas Medicinales/química , Sulfuros/farmacología , Adenosina/química , Adenosina/aislamiento & purificación , Adenosina/farmacología , Animales , Apoptosis/efectos de los fármacos , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/aislamiento & purificación , Estructura Molecular , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/aislamiento & purificación , Células PC12/efectos de los fármacos , Ratas , Receptor de Adenosina A2A/efectos de los fármacos , Suero/metabolismo , Sulfuros/química , Sulfuros/aislamiento & purificaciónRESUMEN
The endogenous neuromodulator adenosine controls and integrates a wide range of brain functions. Consequently, dysfunction of the adenosine system is involved in pathologies ranging from epilepsy to neurodegenerative disorders and psychiatric conditions. The adenosine system has therefore been recognized as a prime target for the development of new therapeutics for neurological diseases. This review covers the upstream and downstream targets of adenosinergic neurotransmission and provides the neurochemical rationale for the development of adenosine receptor modulating drugs (downstream) and inhibitors of adenosine kinase, the key upstream regulator of ambient levels of adenosine. Due to the unique role of adenosine to integrate and fine-tune glutamatergic and dopaminergic neurotransmission, adenosine-regulating agents have the potential to modify a wide range of downstream effects. Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies.
Asunto(s)
Adenosina/metabolismo , Encéfalo/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Adenosina Quinasa/efectos de los fármacos , Adenosina Quinasa/metabolismo , Animales , Encéfalo/metabolismo , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Humanos , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Enfermedades del Sistema Nervioso/fisiopatología , Receptor de Adenosina A1/efectos de los fármacos , Receptor de Adenosina A1/metabolismo , Receptor de Adenosina A2A/efectos de los fármacos , Receptor de Adenosina A2A/metabolismoRESUMEN
BACKGROUND: Reperfusion injury continues to significantly affect patients undergoing lung transplantation. Isolated lung models have demonstrated that adenosine A 2A receptor activation preserves function while decreasing inflammation. We hypothesized that adenosine A 2A receptor activation by ATL-146e during the initial reperfusion period preserves pulmonary function and attenuates inflammation in a porcine model of lung transplantation. METHODS: Mature pig lungs preserved with Viaspan (Barr Laboratories, Pomona, NY) underwent 6 hours of cold ischemia before transplantation and 4 hours of reperfusion. Animals were treated with (ATL group, n = 7) and without (IR group, n = 7) ATL-146e (0.05 microg kg -1 . min -1 ATL-146e administered intravenously for 3 hours). With occlusion of the opposite pulmonary artery, the animal was maintained for the final 30 minutes on the allograft alone. Recipient lung physiology was monitored before tissue evaluation of pulmonary edema (wet-to-dry weight ratio), myeloperoxidase assay, and tissue tumor necrosis factor alpha by means of enzyme-linked immunosorbent assay. RESULTS: When the ATL group was compared with the IR group, the ATL group had better partial pressure of carbon dioxide (43.8 +/- 4.1 vs 68.9 +/- 6.3 mm Hg, P < .01) and partial pressure of oxygen (272.3 +/- 132.7 vs 100.1 +/- 21.4 mm Hg, P < .01). ATL-146e-treated animals exhibited lower pulmonary artery pressures (33.6 +/- 2.1 vs 47.9 +/- 3.5 mm Hg, P < .01) and mean airway pressures (16.25 +/- 0.08 vs 16.64 +/- 0.15 mm Hg, P = .04). ATL-146e-treated lungs had lower wet-to-dry ratios (5.9 +/- 0.39 vs 7.3 +/- 0.38, P < .02), lower myeloperoxidase levels (2.9 x 10 -5 +/- 1.2 x 10 -5 vs 1.3 x 10 -4 +/- 4.0 x 10 -5 DeltaOD mg -1 . min -1 , P = .03), and a trend toward decreased lung tumor necrosis factor alpha levels (57 +/- 12 vs 96 +/- 15 pg/mL, P = .06). The ATL group demonstrated significantly less inflammation on histology. CONCLUSION: Adenosine A 2A activation during early reperfusion attenuated lung inflammation and preserved pulmonary function in this model of lung transplantation. ATL-146e and similar compounds could play a significant role in improving outcomes of pulmonary transplantation.
Asunto(s)
Ácidos Ciclohexanocarboxílicos/uso terapéutico , Modelos Animales de Enfermedad , Trasplante de Pulmón/efectos adversos , Pulmón/irrigación sanguínea , Purinas/uso terapéutico , Receptor de Adenosina A2A , Daño por Reperfusión , Agonistas del Receptor de Adenosina A2 , Animales , Análisis de los Gases de la Sangre , Dióxido de Carbono/sangre , Ácidos Ciclohexanocarboxílicos/inmunología , Evaluación Preclínica de Medicamentos , Ensayo de Inmunoadsorción Enzimática , Femenino , Inflamación , Pulmón/química , Pulmón/inmunología , Pulmón/metabolismo , Trasplante de Pulmón/inmunología , Masculino , Activación Neutrófila , Tamaño de los Órganos , Oxígeno/sangre , Peroxidasa/análisis , Peroxidasa/metabolismo , Edema Pulmonar/diagnóstico , Edema Pulmonar/etiología , Edema Pulmonar/prevención & control , Purinas/inmunología , Distribución Aleatoria , Receptor de Adenosina A2A/efectos de los fármacos , Receptor de Adenosina A2A/fisiología , Daño por Reperfusión/diagnóstico , Daño por Reperfusión/etiología , Daño por Reperfusión/metabolismo , Daño por Reperfusión/prevención & control , Pruebas de Función Respiratoria , Índice de Severidad de la Enfermedad , Porcinos , Factores de Tiempo , Factor de Necrosis Tumoral alfa/análisis , Factor de Necrosis Tumoral alfa/inmunologíaAsunto(s)
Cafeína/administración & dosificación , Café , Enfermedad de Parkinson/prevención & control , Receptor de Adenosina A2A/efectos de los fármacos , Receptores de Dopamina D2/efectos de los fármacos , Antagonistas del Receptor de Adenosina A2 , Animales , Ganglios Basales/efectos de los fármacos , Ganglios Basales/fisiología , Humanos , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/fisiopatología , Receptor de Adenosina A2A/fisiología , Receptores de Dopamina D2/fisiologíaRESUMEN
The aim of the study was to demonstrate competition between caffeine and a fixed valerian/hop extract combination (Ze91019) by the central adenosine mechanism. EEG was used to describe the action of caffeine on the central nervous system after oral administration (200 mg) in healthy volunteers. In addition to caffeine, the volunteers (16 in each group) received either placebo or verum (2 and 6 tablets containing the valerian/hop extract). The EEG responses were recorded every 30 min thereafter. The verum medication was capable of reducing (2 tablets) or inhibiting (6 tablets) the arousal induced by caffeine. This pharmacodynamic action was observed 60 minutes after oral administration, indicating not only competition between the antagonist caffeine and the partial agonist, i. e., the valerian/hop extract but also bio-availability of the compound(s) responsible for the agonistic action. In conclusion, the valerian/hop extract acts via a central adenosine mechanism which is possibly the reason for its sleep-inducing and -maintaining activity.